Collagen Biostimulatorsin Brighton & Hove

For patients who want to understand this properly: what a biostimulator actually is, how it works, how the three materials differ, what gradual collagen stimulation can and cannot change, the real evidence with patient numbers, the honest risks, the course and its variation, and when another treatment — or none — is the better answer. It is long on purpose, and it replaces nothing said in a face-to-face assessment.

01What a biostimulator is

Not a filler that stimulates — a stimulator that scaffolds.

A collagen biostimulator is an injectable material whose purpose is to prompt your own tissue to make new collagen, rather than to occupy space itself. With poly-L-lactic acid the lasting change depends almost entirely on that tissue response; with calcium hydroxyapatite there is also an initial carrier gel and microspheres that give some immediate support before the collagen forms. This is the distinction that explains the gradual onset, the limited reversibility and the different risk profile compared with hyaluronic-acid filler.^[12]

Three materials are relevant at odNOVA, and they are named here for accuracy rather than as a menu: Sculptra (poly-L-lactic acid, the longest-studied and fully gradual), Radiesse (calcium hydroxyapatite microspheres in a gel carrier, giving partial immediate support that converts to stimulated collagen), and Juläine (a newer Swedish poly-L-lactic acid whose published data are still early). None is simply “better”; they behave differently, and the choice is anatomical.

02How it works

A controlled nudge to your own repair biology.

The injected particles — PLLA microparticles or CaHA microspheres — act as a stimulus the tissue treats as something to organise around. Fibroblasts gather and lay down new collagen over the following weeks, and the injected material gradually biodegrades. Because the collagen is produced by your own cells, the result is diffuse tissue support rather than a discrete bolus of gel, and it continues to develop after much of the original material has broken down.^[12]

Think of it as laying down a scaffold and letting the building grow around it: the scaffold is temporary, but what it prompts — your collagen — is what you keep for a time. This also explains the limitations honestly. The response belongs partly to your biology, so it varies from person to person, and there is no enzyme that simply dissolves induced collagen. That is precisely why dosing is conservative and treatment is planned in stages.

03The materials

Sculptra, Radiesse, Juläine — and how they differ.

They share a principle but behave differently in the tissue. Understanding the differences matters more than the brand names.

What is actually placed — and what happens next.

Both groups end in the same place — collagen your own cells made — but they do not get there the same way, and the difference changes what you see, when you see it, and how treatment is planned.

Why they are not interchangeable.

A material that provides no support on the day and one that provides some are answering different questions, even though both end in stimulated collagen. PLLA suits genuine, diffuse loss where the goal is unobtrusive rebuilding over months and where nothing needs to be precise. CaHA suits lower-face and jawline support and firmness, where partial early support is useful, and it is the only one of the two considered for the backs of the hands; its hyperdilute skin-quality use rests on weaker, mostly case-series evidence and is discussed as such. Neither is broadly superior — the evidence does not support that claim for any brand — and the choice is anatomical, decided at assessment from what the tissue has actually lost. Juläine works on the same principle as Sculptra, but its published data are interim, open-label and from a small study,^[9] so it is presented as earlier-stage rather than equivalent.

Product names are given for accurate information, not to be chosen from. What is used — if anything — is decided at assessment, according to the tissue and the objective.

04How it differs from other treatments

Where it sits among everything else.

Biostimulators are easy to confuse with several other treatments that also involve a needle and the word “collagen”. They are not interchangeable.

• Hyaluronic-acid filler occupies space immediately and precisely, and can be dissolved. A biostimulator builds your own tissue slowly and diffusely, and cannot. Filler shapes; a biostimulator supports.
• Skin boosters place hyaluronic acid superficially to hydrate and improve skin quality — they are about the surface, not deep structural volume.
• PRP/PRF uses your own platelets to encourage repair and skin quality; it is regenerative but does not provide the structural, volumising scaffold of a biostimulator.
• Polynucleotides aim at tissue quality and repair signalling, again more about skin condition than structural rebuild.
• Microneedling stimulates collagen at the level of the skin’s surface and texture, not deep volume.
• HIFU and energy devices tighten and lift existing tissue with focused energy — they address laxity, not lost volume.

A biostimulator is the tool for genuine, diffuse loss of deep support. When the problem is really surface quality, precise shape or laxity, one of the above is usually the more direct answer.

05What it may improve

What it may change — in the right face.

• Rebuild diffuse volume across cheeks, temples and the lower face where support has genuinely been lost
• Restore a gaunt or deflated face gradually and unobtrusively
• Support faces changed by significant weight loss
• Improve the firmness and thickness of supporting tissue over a broad area
• Rejuvenate the backs of the hands (calcium hydroxyapatite)

In each case the value comes from replacing lost support, diffusely, over time — not from filling a specific line or projecting a specific point.

06What it cannot do

What it will not do — honestly.

• Give precise projection of the chin, nose or lips — that is hyaluronic-acid filler territory
• Be used in the lips or tear troughs — the nodule risk there is unacceptable^[8]
• Tighten truly lax skin or replace what surgery does
• Treat pigment, pores or surface texture
• Show a meaningful result on the day — or be undone if you change your mind

A biostimulator can restore support the tissue has lost. It cannot replace skin, precise structure or a muscle’s action, and it cannot be previewed or reversed. Keeping those limits clear is part of the treatment, not a caveat to it.

07Areas treated — and never treated

Where it belongs, and where it does not.

Commonly considered: the cheeks and midface, temples, pre-jowl and jawline, the lower face generally, and — for calcium hydroxyapatite — the backs of the hands and, in hyperdilute form, broader skin-quality use across the face, neck and décolletage. The hyperdilute skin-quality use rests on weaker, mostly case-series evidence and is discussed as such.

Never treated with these materials: the lips and the tear troughs. In a large calcium-hydroxyapatite series, the few nodules that occurred were almost entirely in the lips^[8] — which is exactly why those areas are the province of hyaluronic-acid filler or no treatment, not of biostimulators.

08Who may — and may not — suit

Suitability is about the tissue, not the age.

Often a good fit: genuine, diffuse volume loss or tissue thinning; faces after significant weight loss; a wish for gradual, unnoticeable change with patience for months of development; and comfort with an irreversible mechanism, staged dosing and a review-led plan.

Usually not the right step: a wish for immediate or precisely sculpted change; concerns confined to lips, tear troughs or a single line; laxity or excess skin as the main problem; and expectations that cannot accommodate the words “gradual” and “variable”. Certain medical circumstances are also relevant — discussed under suitability below.

09When another route is more direct

Sometimes stimulation is simply the wrong tool.

If your concern is a precise fold or projection, hyaluronic-acid filler is more direct and reversible. If it is surface quality or fine lines, skin boosters, polynucleotides or microneedling fit better. If it is laxity, energy-based tightening or surgical assessment is more honest. If it is expression lines from movement, a muscle-relaxing treatment is the point. Choosing a biostimulator only makes sense once the problem is genuinely one of diffuse, lost support — and sometimes the right answer is no treatment at all.

10Consultation & choosing care

An irreversible treatment deserves an unhurried decision.

Assessment comes first: what has changed in volume, thickness or support, what remains, and whether stimulation genuinely fits the objective. We review medical history, medicines and supplements, any previous products, and take photographs; and the irreversibility is discussed explicitly, not glossed over. New patients have a cooling-off period — there is no routine same-day treatment for a decision that cannot be undone.

Choosing who treats you matters more with biostimulators than with almost anything else, precisely because there is no reversal. Look for a medical professional who assesses before recommending, who explains the limits as clearly as the benefits, who uses named products transparently, and who plans conservatively and in stages. At odNOVA, care is delivered personally by Piotr Wojtowicz, a pharmacist independent prescriber — more about Piotr.

11Preparation, pain & the appointment

What preparing for it, and the visit itself, involve.

Preparing. As before any injectable: discuss blood-thinning medication and supplements at assessment, arrive without active skin infection in the area, and plan any social events at least two weeks away in case of bruising. Alcohol and vigorous exercise are best avoided in the day or two beforehand.

Comfort. Topical anaesthetic is used where appropriate, and some preparations contain lidocaine, so discomfort is usually modest — a series of injections or cannula passes rather than a single sharp event. It is not a pain-free treatment, but it is generally well tolerated.

The appointment takes around 45–60 minutes: planning and product choice on the day, cleansing and anaesthesia, then placement by fine cannula or needle into the planned tissue plane, conservatively dosed. You leave with individual aftercare instructions, including the PLLA massage routine where relevant.

12The first week

Why the first week is misleading (PLLA).

PLLA is reconstituted in sterile fluid, so the face looks fuller on the day — then the fluid absorbs within a few days and the “result” appears to vanish. That is entirely expected. The genuine change builds from around six weeks as collagen forms. Judging PLLA at one week is judging the water, not the treatment — and this is the single most common cause of unnecessary worry. Calcium hydroxyapatite is different: some of its day-one support is real and is maintained as collagen develops.

13Recovery & aftercare

Limited downtime — and why the massage matters.

Expect the possibility of swelling, redness, tenderness and bruising for a few days; most people return to normal activity quickly. For the first days, avoid saunas, intense exercise and firm pressure on the treated area. With PLLA, follow the massage routine exactly as shown — it exists to distribute the material and reduce the risk of nodules, and skipping it is not a shortcut. You receive an individual aftercare note; this summary does not replace it.

14The course

Why it is staged — and judged, not repeated.

Because the result is built by your own tissue and cannot be undone, treatment is deliberately conservative and staged — commonly one to three sessions several weeks apart for PLLA, and one or two for calcium hydroxyapatite, depending on the tissue and objective. Each stage is judged at 6–12 weeks with photographs before deciding on the next: continue, adjust, change mechanism or stop. More vials are never the automatic answer, and building slowly is how an irreversible treatment is kept safe.

15Onset, peak & duration

When results appear, peak, and why they vary.

Why it varies: the result is partly your own biology, so collagen response differs between people; it also depends on the material, the area, how much support was lost, and how the course is staged. These are honest ranges from studies, not a personal guarantee — and duration figures describe groups, not individuals.

16Maintenance & combining

Keeping it up, and working with other treatments.

Because the collagen ages with you, results are maintained rather than permanent — a reassessment closer to two years often guides whether a lighter maintenance stage is worthwhile. Biostimulators can sit sensibly alongside other treatments in a wider plan: hyaluronic-acid filler for a specific projection the stimulation will not give, muscle-relaxing treatment for dynamic lines, or skin-quality treatments for the surface. Sequencing and timing are planned individually; combining is about matching each problem to the right tool, not layering treatments for their own sake.

17Why results vary or disappoint

When it does less than hoped.

Disappointment usually has an explicable cause: judging PLLA too early, when the day-one water has gone but collagen has not yet formed; a genuinely weaker collagen response, which varies between people; too few stages for the degree of loss; or — most importantly — the wrong problem, where the real issue was skin quality, precise shape or laxity that stimulation was never going to fix. This is why each stage is judged with photographs and why the honest option is sometimes to change mechanism or to stop, rather than to add more material.

18Why some outcomes look unnatural

When it looks overdone.

Done well, biostimulation is quiet — a face that looks rested rather than treated. Unnatural results come from over-treatment: chasing volume past what the face has lost, treating a heavy or already-full face, or repeating stages before judging the last. Because the material cannot be dissolved, over-correction is far harder to walk back than with hyaluronic acid, which is the strongest argument for building conservatively and stopping at “enough” rather than “more”.

19Safety & risks

Expected, less common, and rare-but-serious.

Every risk below is grouped by how often it occurs and paired with what the frequency depends on and what reduces it. Rates are material-, area- and technique-specific, and where a true frequency is not reliably known, that is said plainly rather than estimated.

Expected & temporary

Less common

Rare but serious

20Serious complications & management

What to watch for — and what we do.

Management is honest about the material. A delayed nodule or inflammatory reaction may be treated with time, massage, anti-inflammatory measures, injected steroid or, occasionally, minor procedures — not a simple dissolving injection. A vascular event is a medical emergency handled by established protocols; the absence of a reversal enzyme is exactly why prevention, conservative technique and prompt recognition carry so much weight here.

21Who may not be suitable

Contraindications & cautions.

• Pregnancy or breastfeeding — not treated
• Active infection or inflammation in the treatment area
• A history of significant inflammatory or autoimmune skin disease in the area — discussed individually
• A tendency to keloid or abnormal scarring, or known hypersensitivity to a product component
• Unrealistic or immovable expectations, or an inability to accept an irreversible, gradual result
• Certain bleeding disorders or blood-thinning medication — assessed individually before any decision

This is not an exhaustive list; suitability is decided at a full assessment, and treatment is declined where it is not clearly in your interest.

22Alternatives

The honest alternatives.

• Precise shape or a single fold — hyaluronic-acid filler, immediate and largely reversible
• Skin quality & texture — skin boosters, polynucleotides, microneedling or PRP/PRF
• Laxity & descent — HIFU or surgical assessment
• Dynamic expression lines — muscle-relaxing treatment
• Mild, accepted change — no treatment, a legitimate and often wise choice

23Fees

Fees

Because treatment is usually staged, the useful figure is the likely course rather than one isolated vial. What you need — if anything — is confirmed at assessment. The £50 consultation fee is added to your patient account as clinic credit.

Product and quantity are selected according to the tissue, objective and full treatment plan. Full fees: fees.

24Questions, answered

Biostimulators — answered.

25Evidence map

What the evidence supports — and what it does not.

Every card below reports what actually happened to patients in a study: how many took part, how many improved, by how much and measured how, when it began, how long it lasted, how satisfied they were, what went wrong and in how many, and what it means for a real decision. Results are kept separate by material and by area and are not interchangeable — a number for one product, indication or region does not transfer to another. Product names, doses, volumes and the rules on eligibility are not evidence and are handled elsewhere on this page and in the references.

The overall picture: the evidence is strongest and most consistent for restoring genuine, diffuse volume loss with PLLA and for correcting folds and supporting the lower face with CaHA, and for the general shape of gradual onset and one-to-two-year duration. It is weaker or absent for skin-quality “glow” claims measured only by satisfaction questionnaires, for “collagen banking” in young faces without demonstrable loss, for any claim that one brand is broadly superior to another, and for the newest product (Juläine), where the data are still interim. Where the evidence is thin, this page says so.

Gradual stimulation is valuable when the problem is genuinely lost, diffuse support. It is the wrong tool for precise shape, surface quality or laxity — and sometimes the right answer is no treatment.

26References

References & sources

Sources are primary clinical studies, long-term follow-up, large clinical series and reviews, with regulators used only for legal and approval context. Where evidence is limited or product-specific, that is stated in the text. Access date 23 July 2026.

1. PLLA nasolabial folds, durability to 25 months (RCT, n=234): Narins RS, Baumann L, Brandt FS, et al. (2010) ‘A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles’, J Am Acad Dermatol, 62(3), pp. 448–462. Available at: pubmed.ncbi.nlm.nih.gov/20159310/ (Accessed: 23 July 2026).
2. PLLA for HIV facial lipoatrophy, review of four studies (VEGA/Chelsea & Westminster/APEX-002/Blue Pacific): Barton SE, Engelhard P, Conant M. (2006) ‘Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies’, Int J STD AIDS. Available at: journals.sagepub.com/doi/10.1258/095646206777689116 (Accessed: 23 July 2026).
3. PLLA lipoatrophy, 48-week & 18-month outcomes and nodule rate (~10%): Moyle GJ, Brown S, Lysakova L, Barton SE. (2006) ‘Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy’, HIV Medicine. Available at: pubmed.ncbi.nlm.nih.gov/16494632/ (Accessed: 23 July 2026).
4. VEGA study — early nodule rate (44% at 96 weeks) with superseded technique: Valantin MA, Aubron-Olivier C, Ghosn J, et al. (2003) ‘Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA’, AIDS, 17(17), pp. 2471–2477. Available at: pubmed.ncbi.nlm.nih.gov/14600518/ (Accessed: 23 July 2026).
5. PLLA HIV & ageing lipoatrophy, 3-year prospective cohort (n=65): Mest DR, Humble GM. (2009) ‘Treatment of HIV lipoatrophy and lipoatrophy of ageing with poly-L-lactic acid: a prospective 3-year follow-up study’, J Am Acad Dermatol. Available at: sciencedirect.com/science/article/abs/pii/S0190962208009298 (Accessed: 23 July 2026).
6. CaHA nasolabial folds pivotal split-face trial (n=117) & over-a-decade review: van Loghem J, Yutskovskaya YA, Werschler WP. (2015) ‘Calcium hydroxylapatite: over a decade of clinical experience’, J Clin Aesthet Dermatol, 8(1), pp. 38–49. Available at: ncbi.nlm.nih.gov/pmc/articles/PMC4295857/ (Accessed: 23 July 2026).
7. CaHA nasolabial folds, 3-year long-term follow-up (102 of 117; 40% of folds improved at ≥30 months): Bank DE, et al. (2010) ‘Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results’, Aesthet Surg J, 30(2), pp. 235–238. Available at: academic.oup.com/asj/article-abstract/30/2/235/345209 (Accessed: 23 July 2026).
8. CaHA large series (n=1,000), 12-month persistence >80%, nodules rare and lip-confined: Bass LS, Smith S, Busso M, McClaren M. (2008) ‘A 52-month summary of results using calcium hydroxylapatite for facial soft-tissue augmentation’, Dermatol Surg. Available at: ovid.com — 52-month summary of calcium hydroxylapatite results (Accessed: 23 July 2026).
9. Juläine (PLLA-LaSynPro) nasolabial folds, interim open-label study (n=36): Urdiales-Gálvez F, Benítez PA, Díaz I. (2025) ‘Facial rejuvenation with an innovative poly-L-lactic acid (Juläine) for nasolabial folds: interim data analysis of a prospective, non-randomised, multicentre, open-label Spanish study’, J Cosmet Dermatol. Available at: ncbi.nlm.nih.gov/pmc/articles/PMC11938402/ (Accessed: 23 July 2026).
10. Next-generation PLLA-microsphere nasolabial-fold RCT (context, product-specific durability to 48 weeks): (2025) ‘Long-term correction of nasolabial folds using poly-L-lactic acid microspheres: a multicentre, double-blinded, randomised trial’, J Cosmet Dermatol / PMC. Available at: ncbi.nlm.nih.gov/pmc/articles/PMC12903950/ (Accessed: 23 July 2026).
11. Under-18 prohibition (England) — legal context: GOV.UK (2021) ‘Botulinum toxin and cosmetic fillers for under-18s’. Available at: gov.uk — botulinum toxin and cosmetic fillers for under-18s (Accessed: 23 July 2026).
12. Mechanism & regenerative biology of PLLA (neocollagenesis, fibroblast activation) — systematic review: (2025) ‘Poly-L-lactic acid in aesthetic dermatology: a decade beyond volume restoration toward regenerative biostimulation’, Aesthet Surg J, 45(10), p. 1065. Available at: academic.oup.com/asj/article/45/10/1065/8171359 (Accessed: 23 July 2026).
13. Regulatory approvals for PLLA and CaHA (approved uses) — context: U.S. Food & Drug Administration. ‘Dermal fillers (soft-tissue fillers) — approved uses’. Available at: fda.gov/medical-devices/aesthetic-cosmetic-devices/dermal-fillers-soft-tissue-fillers (Accessed: 23 July 2026).

This page is general information about a medical procedure — not individual medical advice, a recommendation, or an advertisement. Suitability is decided only after a face-to-face assessment and treatment is never guaranteed.